Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Synlogic, Inc. (SYBX)

0.73   -0.01 (-1.35%) 12-06 09:47
Open: 0.79 Pre. Close: 0.74
High: 0.74 Low: 0.7178
Volume: 8,990 Market Cap: 51(M)

Technical analysis

as of: 2022-12-06 9:51:29 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.02     One year: 1.19
Support: Support1: 0.67    Support2: 0.55
Resistance: Resistance1: 0.87    Resistance2: 1.02
Pivot: 0.66
Moving Average: MA(5): 0.71     MA(20): 0.67
MA(100): 0.94     MA(250): 1.42
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 79.3     %D(3): 70.6
RSI: RSI(14): 50.1
52-week: High: 2.65  Low: 0.55
Average Vol(K): 3-Month: 150 (K)  10-Days: 177 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SYBX ] has closed below upper band by 21.7%. Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.79 - 0.79 0.79 - 0.8
Low: 0.71 - 0.72 0.72 - 0.72
Close: 0.73 - 0.74 0.74 - 0.75

Company Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; SYNB2081 to lower uric acid for the potential treatment of gout; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 01 Dec 2022
Biotech layoffs 2022: Cell therapy-focused SQZ Biotechnologies lays off most of its staff, ousts CEO - Boston Business Journal - The Business Journals

Wed, 30 Nov 2022
Synlogic (SYBX) Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update - StreetInsider.com

Wed, 23 Nov 2022
Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation - Simply Wall St

Thu, 10 Nov 2022
Synlogic Earnings Miss, Revenue Beats In Q3 By Investing.com - Investing.com

Tue, 06 Sep 2022
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease - Yahoo Finance

Thu, 11 Aug 2022
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 71 (M)
% Held by Insiders 4.518e+007 (%)
% Held by Institutions 9.6 (%)
Shares Short 210 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.274e+007
EPS Est Next Qtl 0
EPS Est This Year -3.21
EPS Est Next Year -1.5
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 917.2
Return on Equity (ttm) -25.6
Qtrly Rev. Growth 1.67e+006
Gross Profit (p.s.) -23.01
Sales Per Share -43.61
EBITDA (p.s.) 1.54867e+006
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -58 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.58

Stock Dividends

Dividend 0
Forward Dividend 179460
Dividend Yield 0%
Dividend Pay Date 2017-08-27
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.